Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Drugs
941-960 of 1,320 results
-
-
Insulin’s Steep Price Leads To Deadly Rationing
Alec Raeshawn Smith was 23 when diagnosed with Type 1 diabetes, and 26 when he died. He couldn't afford $1,300 per month for his insulin and other diabetes supplies. So he tried to stretch the doses.
-
The High Cost Of Hope: When The Parallel Interests Of Pharma And Families Collide
Desperate for help in finding a lifesaving drug for a fatal genetic disease, families banded together to fund early research and then worked with drug companies on clinical trials and marketing. Yet, this small patient advocacy group is stunned by pharma’s pricing.
By Emily Kopp and Jay Hancock -
States Looking To Tax Opioids Pin Hopes On November Elections
At least 11 states are going to try to tax opioids despite pushback from pharmaceutical companies.
By Jay Hancock and Shefali Luthra -
Giuliani’s Consulting Firm Helped Halt Purdue Opioid Investigation In Florida
Post-9/11, Giuliani Partners helped craft a plan that put a halt to a probe into Purdue’s marketing of OxyContin.
By Fred Schulte -
Lawmakers Push To Protect Patients And Counter Trump
California legislators approved some significant health care proposals in their rush to meet the Friday end-of-session deadline. They tackled controversial topics, such as making abortion pills available on college campuses, and adopted measures countering Trump administration attacks on the Affordable Care Act.
-
Podcast: KHN’s ‘What The Health?’ Ask Us Anything!
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico answer listeners’ questions about health policy and politics.
-
Podcast: KHN’s ‘What The Health?’ Opioids, EpiPens And Health Funding
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico discuss Senate action on health funding and opioid legislation, the state of the individual insurance market and consternation over expiration dates on EpiPens, the self-injected allergy remedy. Also, could an otter with asthma signal a potential public health crisis?
-
Rehabilitation Plus Rehab? Jails Dispense Drugs To Treat Inmates’ Addictions
Rather than go cold turkey, inmates increasingly have the option to take medication to help beat addiction to opioids and other substances. But some warn these substitute drugs serve as another crutch — and a costly one at that.
By Anna Gorman -
The Man Who Sold America On Vitamin D — And Profited In The Process
The doctor most responsible for turning the sunshine supplement into a billion-dollar juggernaut has received hundreds of thousands of dollars from the vitamin D industry, according to government records and interviews.
By Liz Szabo -
Purdue Pharma’s Sales Pitch Downplayed Risks Of Opioid Addiction
Through a widely circulated brochure and a videotape of testimonials, the maker of OxyContin stressed patients’ right to opioid treatment for pain.
By Fred Schulte -
Podcast: KHN’s ‘What The Health?’ See You In Court!
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Margot Sanger-Katz of The New York Times and Kimberly Leonard of the Washington Examiner talk about a spate of lawsuits involving the Affordable Care Act, as well as the latest in state and federal efforts regarding the Medicaid program for the poor.
-
Advances In Treating Hep C Lead To New Option For Transplant Patients
The opioid epidemic has increased the number of donated organs. Until recently, though, organs from donors who died of drug overdoses were often discarded because an estimated 30 percent of them were infected with hepatitis C.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
-
Trump Administration Sinks Teeth Into Paring Down Drug Prices, On 5 Key Points
Instead of waiting for congressional action, federal regulators are looking at a series of actions to spur competition and drive down the cost of medicines.
-
Clinicians Who Learn Of A Patient’s Opioid Death Modestly Cut Back On Prescriptions
A study published Thursday shows that doctors, dentists and other medical providers cut overall opioid dosages by nearly 10 percent after receiving notification of a death from a medical examiner and information on safe prescribing.
By Anna Gorman -
Podcast: KHN’s ‘What The Health?’ Coming Soon: ‘Long-Term Short-Term’ Plans
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Margot Sanger-Katz of The New York Times and Kimberly Leonard of the Washington Examiner talk about the latest Trump administration efforts to address high drug prices, what’s next for short-term health insurance plans and insider trading charges against a New York GOP congressman.
-
Pharmacy-Made Pain Creams Flagged On Fears Of Medicare Fraud And Risk
Inspector general identifies possible problems in nearly 23 percent of pharmacies that bill Medicare for blended creams, gels and lotions.
-
As An Investor In Biotech Stock, Republican Chris Collins May Have Overshared
Rep. Chris Collins talked one time too many, according to federal prosecutors who on Wednesday charged him with violating insider trading laws.
-
GOP Congressman Chris Collins Indicted On Insider Trading Charges
The New York congressman was a major investor in an Australian biotechnology firm and prosecutors allege that he tipped off his son and others to sell stock shortly before the company reported poor results in its drug testing.